• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Serum soluble CD163 levels in patients with influenza-associated encephalopathy

tetano

Editor, Senior Moderator
Brain Dev. 2012 Nov 10. pii: S0387-7604(12)00263-X. doi: 10.1016/j.braindev.2012.10.005. [Epub ahead of print]
Serum soluble CD163 levels in patients with influenza-associated encephalopathy.
Hasegawa S, Matsushige T, Inoue H, Takahara M, Kajimoto M, Momonaka H, Ishida C, Tanaka S, Morishima T, Ichiyama T.
Source

Department of Pediatrics, Yamaguchi University, Graduate School of Medicine, Japan. Electronic address: shunji@yamaguchi-u.ac.jp.
Abstract

Background: Influenza-associated encephalopathy (IE) is a serious complication during influenza viral infection. Common clinical symptoms of IE include seizures and progressive coma with high-grade fever. We previously reported that hypercytokinemia and monocyte/macrophage activation may play an important role in the pathogenesis of IE. CD163 is a scavenger receptor for hemoglobin-haptoglobin complexes and is expressed by monocytes/macrophages. Proteolytic cleavage of monocyte-bound CD163 by matrix metalloproteinases releases soluble CD163 (sCD163). However, there have been no reports regarding serum sCD163 levels in IE patients. Methods: We measured serum levels of sCD163 as a marker of monocyte/macrophage activation in IE patients with poor outcomes, those without neurological sequelae, influenza patients without IE, and control subjects. Results: Serum sCD163 levels were significantly higher in IE patients with poor outcomes than in those without neurological sequelae. In particular, sCD163 levels in cases of death were significantly higher than those in other cases. Conclusions: Our results suggest that monocyte/macrophage activation is related to the pathogenesis of severe IE.

Copyright ? 2012 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

PMID:
23149357
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23149357
 
Back
Top Bottom